Journal
MOLECULAR THERAPY
Volume 23, Issue 6, Pages 993-1002Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2015.50
Keywords
-
Categories
Funding
- E.U. [264083]
- Hellenic General Secretariat for Research and Technology [09SYN-21-969]
- Foundation BNP Paribas
- Empeirikion Foundation
- European Regional Development Fund and national resources
- Landesexzellenzinitiative (LEXI) of Hamburg Nanotechnology in Medicine (NAME)
- European Molecular Biology Organization (EMBO) [ASTF: 87-2012]
- Theodore-Theochari Cozzika Foundation
Ask authors/readers for more resources
Failure of the mammalian central nervous system (CNS) to regenerate effectively after injury leads to mostly irreversible functional impairment. Gold nanoparticles (AuNPs) are promising candidates for drug delivery in combination with tissue-compatible reagents, such as polyethylene glycol (PEG). PEG administration in CNS injury models has received interest for potential therapy, but toxicity and low bioavailability prevents clinical application. Here we show that intraspinal delivery of PEG-functionalized 40-nm-AuNPs at early stages after mouse spinal cord injury is beneficial for recovery. Positive outcome of hind limb motor function was accompanied by attenuated inflammatory response, enhanced motor neuron survival, and increased myelination of spared or regrown/sprouted axons. No adverse effects, such as body weight loss, ill health, or increased mortality were observed. We propose that PEG-AuNPs represent a favorable drug-delivery platform with therapeutic potential that could be further enhanced if PEG-AuNPs are used as carriers of regeneration-promoting molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available